Literature DB >> 19141094

Improved outcome in Wegener's granulomatosis and microscopic polyangiitis? A retrospective analysis of 95 cases in two cohorts.

P Eriksson1, L Jacobsson, A Lindell, J-A Nilsson, T Skogh.   

Abstract

OBJECTIVES: Mortality rates for Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA) have decreased after the introduction of cyclophosphamide. Standardized mortality ratio (SMR) expresses the overall mortality of patients compared with the general population. The aims of this study were to compare survival in an old and a recent cohort of patients with WG and MPA using SMR and to determine predictors for death in both groups combined.
DESIGN: Survival analyses were performed by Kaplan-Meier survival curves, SMR and proportional hazards regression models.
SETTING: The nephrology and rheumatology clinics at Linköping University Hospital, Sweden.
SUBJECTS: All patients diagnosed with WG or MPA in the catchment area during 1978-2005 were divided into two cohorts; patients diagnosed before (n=32, old cohort) and after (n=63, recent cohort) December 31, 1996.
RESULTS: The two cohorts differed regarding the proportion of WG (75% vs. 56%, P=0.03) and a tendency for more pronounced kidney involvement in the old cohort: 266 micromol L(-1) (16% dialysis-dependent) vs. 192 micromol L(-1) (5% dialysis-dependent), but were comparable regarding disease severity. SMR at 1 and 5 years were 2.1 (95% CI: 0.43-6.09) and 1.6 (95% CI: 0.6-3.2) in the recent cohort and 5.2 (95% CI: 1.07-15.14) and 2.5 (95% CI: 0.93-5.52) in the old cohort. Five-year survival was 87% and 81%. Serum creatinine, age, end-stage renal disease, diagnosis before 1997 and first relapse were independent predictors for death.
CONCLUSION: Patient survival in WG and MPA analysed with SMR may be better than previously believed. Severe renal disease and disease relapse were the major predictors of reduced survival.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19141094     DOI: 10.1111/j.1365-2796.2008.02060.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  19 in total

Review 1.  Complications of long-term therapy for ANCA-associated systemic vasculitis.

Authors:  Nadezhda Wall; Lorraine Harper
Journal:  Nat Rev Nephrol       Date:  2012-06-05       Impact factor: 28.314

2.  All-cause and cause-specific mortality in ANCA-associated vasculitis: overall and according to ANCA type.

Authors:  Zachary S Wallace; Xiaoqing Fu; Tyler Harkness; John H Stone; Yuqing Zhang; Hyon Choi
Journal:  Rheumatology (Oxford)       Date:  2020-09-01       Impact factor: 7.580

3.  Outcome and treatment of elderly patients with ANCA-associated vasculitis.

Authors:  Maria Weiner; Su Mein Goh; Aladdin J Mohammad; Zdenka Hruskova; Anisha Tanna; Annette Bruchfeld; Daina Selga; Zdenka Chocova; Kerstin Westman; Per Eriksson; Charles D Pusey; Vladimir Tesar; Alan D Salama; Mårten Segelmark
Journal:  Clin J Am Soc Nephrol       Date:  2015-06-22       Impact factor: 8.237

4.  Determinants of renal and patient outcomes in a Spanish cohort of patients with ANCA-associated vasculitis and renal involvement.

Authors:  H Marco; J Draibe; J Villacorta; L F Quintana; N Martin; R Garcia-Osuna; C Cabre; M A Martín-Gómez; A Balius; A Saurina; M Picazo; I Gich-Saladich; M Navarro-Díaz; M Praga; T Cavero; J Ballarin; M M Díaz-Encarnación
Journal:  Clin Rheumatol       Date:  2018-03-09       Impact factor: 2.980

5.  Pulmonary arterial hypertension associated with rare cause of ANCA-associated vasculitis misdiagnosed as idiopathic one.

Authors:  Yi Li; Qun Yi
Journal:  Int J Clin Exp Med       Date:  2015-09-15

Review 6.  Granuloma in ANCA-associated vasculitides: another reason to distinguish between syndromes?

Authors:  Antje Mueller; Konstanze Holl-Ulrich; Wolfgang L Gross
Journal:  Curr Rheumatol Rep       Date:  2013-11       Impact factor: 4.592

Review 7.  [Development of morbidity and mortality in ANCA-associated vasculitis].

Authors:  E Reinhold-Keller; F Moosig
Journal:  Z Rheumatol       Date:  2011-08       Impact factor: 1.372

8.  Improved survival in granulomatosis with polyangiitis: A general population-based study.

Authors:  Zachary S Wallace; Na Lu; Sebastian Unizony; John H Stone; Hyon K Choi
Journal:  Semin Arthritis Rheum       Date:  2015-08-03       Impact factor: 5.532

9.  Trends in Long-Term Outcomes Among Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Renal Disease.

Authors:  Rennie L Rhee; Susan L Hogan; Caroline J Poulton; Julie Anne G McGregor; J Richard Landis; Ronald J Falk; Peter A Merkel
Journal:  Arthritis Rheumatol       Date:  2016-07       Impact factor: 10.995

10.  [Update on granulomatosis with polyangitis (GPA, Wegener's granulomatosis)].

Authors:  J U Holle; E Reinhold-Keller; W L Gross
Journal:  Z Rheumatol       Date:  2012-11       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.